What this is
- How it works
- How it works isn't classified yet
- Tested for
- Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
- Main trialPhase 1/2
- “This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a one-time injection into the retina (subretinal space) of the worse-seeing eye, using a method similar to approved gene therapies like Luxturna. The study is designed to evaluate safety and effectiveness at two dose levels (1E11 and 3E11 viral genomes per eye) in small groups of 5 participants. Each group begins…”In the company’s words, NCT07681778 on ClinicalTrials.gov
Other drugs for Leber Congenital Amaurosis
- Voretigene neparvovec-rzylSpark Therapeutics, Inc. · Phase 3
- SepofarsenLaboratoires Thea · Phase 3
- OCU400Ocugen · Phase 1/2
- ATSN-101Atsena Therapeutics Inc. · Phase 1/2
Coming up1
- Dec 2032Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2032 | Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026